 Genetic Technologies Limited ASX: GTG; NASDAQ: GENE the Company, a leader in the development of genetic risk assessment tests, today announced that it has priced a public offering of 4,000,000 American Depositary Shares ADSs or ADS equivalents, each representing six hundred 600 of the Companys ordinary shares, at an effective purchase price of 2.00 per ADS or ADS equivalent. H.C. Wainwright Co. is acting as the exclusive placement agent for the offering. The gross proceeds from this offering are expected to be 8.0 million, before deducting the placement agents fees and other offering expenses payable by the Company. 